Altimmune Long Term Debt 2010-2025 | ALT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Altimmune long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Altimmune long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$75.9B
Zoetis (ZTS)	$67.3B
Takeda Pharmaceutical (TAK)	$46.3B
Daiichi Sankyo, - (DSNKY)	$45.5B
BeOne Medicines - (ONC)	$32.4B
Sandoz Group AG (SDZNY)	$25.8B
Summit Therapeutics (SMMT)	$19.7B
Merck (MKKGY)	$16.7B
Shionogi (SGIOY)	$14B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.1B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.3B
Stevanato Group S.p.A (STVN)	$7.4B
Corcept Therapeutics (CORT)	$7.3B
Madrigal Pharmaceuticals (MDGL)	$7B
Ionis Pharmaceuticals (IONS)	$6.7B
Grifols, S.A (GRFS)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Procaps Group, S.A (PROCF)	$3.2B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B